Eprenetapopt Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: COCC1(CO)C(=O)C2CCN1CC2
  • InChIKey: BGBNULCRKBVAKL-UHFFFAOYSA-N
  • Mol. Mass: 199.25
  • ALogP: -0.34
  • ChEMBL Molecule:
    eprenetapopt  
More Chemistry

Pharmacology

Alternative names

2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one | apr-246 | prima-1(met)

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Transitional Cell (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 1/Phase 2)

GATA2 Deficiency (Phase 2)

Hematologic Neoplasms (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1/Phase 2)

Melanoma (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Ovarian Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1/Phase 2)

Urinary Bladder Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue